Many cytopathologists regard the 10% rescreening regulation of the Center for Disease Control and Social Security Administration as an unsatisfactory procedure for internal monitoring of cytoscreener performance [in human diagnosis]. The principal deficiencies acutally lie in lack of specified performance criteria and an associated decision rule. By specifying these missing components of a monitoring procedure, the basic elements of a monitoring strategy are obtained as attribute acceptance sampling plans. The acceptance sampling approach to monitoring cytoscreener performance by rescreening negative slides is discussed.